Federal Circuit rejects bio patent citing Bilski
A patent covering diagnostic method claims was rejected by the US Court of Appeals for the Federal Circuit on Friday based on the Court’s controversial decision in In re Bilski, which changed the test for determining patent-eligible subject matter in the US
Although the opinion was non-precedential, it could have significant implications for the biotechnology industry.
The patent at issue (number 5,723,283) covers a "method of immunization, and compositions therefore ... for substantially preventing or reducing the symptoms of at least one...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.